Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2020 · 10-K
Revenue$21.45M$21.45M+82.2% vs Q4 2019 Net Income-$46.24M-$46.24MN/M vs Q4 2019 EPS Diluted-$1.24-$1.24N/M vs Q4 2019 Operating Incomederived-$53,651,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Operating Cash Flowderived$39,468,000N/M Free Cash Flowderived$26,579,000N/M Margins · derivedOperating margin-250.2%+92.5 pt vs Q4 2019
Net margin-215.6%+9.3 pt vs Q4 2019
ended Dec 31, 2020 · filed Mar 1, 2021 · 60 d after period end